1.
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine,...
2.
Cost-effectiveness analysis of herpes zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts : a comparison between no vaccination, the adjuvanted subunit vaccine,...
3.
Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
4.
5.
6.
7.